RSS Feeds
Treatment of Chronic Immune Thrombocytopenic Purpura
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
To my knowledge, no prognostic factors predict successful or poor outcomes after accessory splenectomy. I would suspect that patients with large splenic remnants or who have late relapses after splenectomy would be more likely to respond to accessory splenectomy, but these suspicions are not based on any data. I would also suspect that the response rate of 57%, as calculated by Dr. Kao, is high because reports of successful outcomes to treatment are more likely to be published than those of unsuccessful ones. In any case, I believe that accessory spleens should be removed (unless there are medical contraindications) because the treatment of refractory patients with other forms of therapy is associated with considerable morbidity; successful accessory splenectomy obviates this morbidity.
As stated by Dr. Pavletic, the use of allogeneic or autologous transplantation may offer another treatment approach for carefully selected patients with severe refractory chronic immune thrombocytopenic purpura. As a physician who spends most of his time involved with autologous and allogeneic transplantation, I would add a note of caution. Patients with this condition who are considered candidates for transplantation should be chosen very carefully because these procedures are associated with their own morbidity and mortality (probably <5% with autologous transplantation and >10% with allogeneic transplantation). In addition, should the antiplatelet autoantibody persist in a patient after transplantation, the platelet count may not recover quickly; thus, platelet support would be difficult or impossible. Clearly, a small group of patients with chronic immune thrombocytopenic purpura is resistant to all other forms of therapy, has almost constant mucosal bleeding, and will almost certainly die of the disease. This is the group that should be considered for transplantation. Unfortunately, these patients are also the ones who are most likely to have transplantation-related complications and those who are least likely to respond.
- Copyright ©2004 by the American College of Physicians
